Your session is about to expire
← Back to Search
BST-236 + Venetoclax for Acute Myeloid Leukemia
Study Summary
This trial will assess the safety and efficacy of BST-236 in combination with venetoclax for adult patients with newly diagnosed AML.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I cannot receive standard chemotherapy.I haven't taken strong or moderate CYP3A inducers in the last 7 days.I haven't had surgery, except for minor procedures, in the last 14 days.I have received treatment for acute myeloid leukemia.I have acute promyelocytic leukemia.My leukemia has spread to my brain or spinal cord.I was diagnosed with a cancer other than AML in the last year.I have had a bone marrow or stem cell transplant.I cannot take drugs by mouth due to a digestive condition.I do not have an ongoing serious infection that isn't getting better with treatment.I do not have severe heart problems like unstable chest pain, irregular heartbeat, or advanced heart failure.I am 18 years old or older.I am under 75 and can care for myself but may not be able to do heavy physical work.I am 75 or older and can care for myself.I have a history of blood cancer known as MPN.I haven't taken any experimental drugs within the last 30 days.My only AML symptom is a tumor outside the bone marrow.I am allergic to certain chemotherapy drugs similar to BST-236, cytarabine, or venetoclax.I have been treated for MDS with specific medications.I have been diagnosed with AML, either new or due to previous conditions or treatments.
- Group 1: Treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are participating in this clinical trial?
"That is correct. The information available on clinicaltrials.gov verifies that this trial, which was first announced on 8/17/2022, is still recruiting patients. In total, they are looking for 80 individuals across 2 sites."
Does this age group fall outside of the parameters for this clinical trial?
"According to the age requirements for participation that are listed in the inclusion criteria, the youngest somebody can be is 18 and the oldest they can be is 90."
How can I get involved in this clinical trial?
"This trial is seeking 80 individuals who have recently been diagnosed with adult acute myeloid leukemia and are between 18-90 years old. The most notable requirements for candidates include: being adults ≥18 years of age, a diagnosis of AML that has not responded to prior treatment, an inability to receive standard induction chemotherapy, a white blood cell count of <25,000/μL, AST and/or aALT ≤2.5 X ULN), Total bilirubin ≤1.5 x ULN, 0 to 2 for patients ≥75 years of age, Women of reproductive potential must have a negative serum pregnancy test within"
Are people still being accepted into this experiment?
"Yes, this is an ongoing clinical trial that is currently recruiting patients. According to the latest update on 8/17/2022, they are looking for 80 patients at 2 sites."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger